Synosia acquires HPPD inhibitor from Syngenta
Privately-held USA-based Synosia Therapeutics has acquired a license from Syngenta AG of Switzerland to develop a potentially novel treatment for Parkinson's disease, the third pharmaceutical agreement to be announced by Synosia, which started operations at the beginning of this year to develop new treatments for disorders of the central nervous system.
The compound, called SYN-118, is a hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor, and is already approved in the USA and Europe for the treatment of hereditary tyrosinemia type 1, a life-threatening metabolic disorder. The drug is marketed by Swedish Orphan International under the name Orfadin (nitisinone), under license from Syngenta.
Under the terms of the deal, Synosia will assume responsibility for the ongoing clinical development and commercialization of SYN-118 in CNS. Contingent upon progress, Syngenta will receive milestone payments and royalties. Further financial details were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze